Services on Demand
Journal
Article
Spanish (pdf)
Article in xml format
Article references
Automatic translation
Send this article by e-mailIndicators
Cited by SciELO 
Access statistics
Related links
Cited by Google 
Similars in
SciELO 
Similars in Google
Share
Permalink
Revista Colombiana de Reumatología
Print version ISSN 0121-8123
Abstract
MORA, Claudia et al. Prevalence of latent tuberculosis determined using the Purified Protein Derivative (PPD) test in adult patients with rheumatoid arthritis receiving biotechnological therapy. Rev.Colomb.Reumatol. [online]. 2021, vol.28, n.3, pp.178-183. Epub Jan 16, 2022. ISSN 0121-8123. https://doi.org/10.1016/j.rcreu.2020.08.004.
Introduction:
Although tuberculosis (TB) is endemic in Columbia, with a prevalence of 26 cases per million, there are no recent and clear data regarding the prevalence of latent tuberculosis (LBT) in the population with rheumatoid arthritis (RA), candidates for biotechnological therapy.
Methodology:
A cross-sectional study with an analytical component to determine the prevalence of LBT in patients with RA who are candidates for biotechnological therapy.
Results:
The prevalence of LTB in RA patients who are candidates for biotechnological therapy is high, 18.3% (95% CI: 14.7-21.9). In the exploratory analysis, a relationship between LBT and male gender was found (P ≤ .001), as well as abnormal findings on chest radiography (P = .039), and smoking (P = .028).
Conclusion:
The prevalence of LTB in patients with RA who are candidates for biotechnological therapy is high. Prospective studies are needed to evaluate the incidence of TB in this group of patients and corroborate this association.
Keywords : Latent tuberculosis; Tuberculosis; Rheumatoid arthritis; Biotechnological therapy; Anti-TNF; Rheumatic diseases; Prevalence.
